Profile data is unavailable for this security.
About the company
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
- Revenue in EUR (TTM)1.11bn
- Net income in EUR56.58m
- Incorporated2017
- Employees3.50k
- LocationDermapharm Holding SELil-Dagover-Ring 7GRUENWALD 82031GermanyDEU
- Phone+49 89641860
- Fax+49 8 964186130
- Websitehttps://ir.dermapharm.de/
Holder | Shares | % Held |
---|---|---|
Mawer Investment Management Ltd.as of 29 Jun 2023 | 1.62m | 3.00% |
Grandeur Peak Global Advisors LLCas of 30 Apr 2024 | 814.13k | 1.51% |
Norges Bank Investment Managementas of 31 Dec 2023 | 635.45k | 1.18% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 603.33k | 1.12% |
Janus Henderson Investors UK Ltd.as of 31 May 2024 | 560.26k | 1.04% |
Danske Bank A/S (Investment Management)as of 30 Jun 2024 | 399.21k | 0.74% |
Amundi Asset Management SA (Investment Management)as of 03 Jul 2024 | 352.75k | 0.66% |
Lupus alpha Asset Management AGas of 31 Dec 2023 | 337.00k | 0.63% |
DNCA Finance SAas of 29 Dec 2023 | 276.47k | 0.51% |
Dimensional Fund Advisors LPas of 04 Jul 2024 | 263.54k | 0.49% |